Immunoglobulin reduced in thrombogenic agents and preparation thereof

Patent metadata

Field	Value
Publication number	US-9796770-B2
Application number	US-201514678319-A
Country	US
Kind code	B2
Filing date	Apr 3, 2015
Priority date	May 16, 2011
Publication date	Oct 24, 2017
Grant date	Oct 24, 2017

Abstract

The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.

First claim

The invention claimed is:

1. A method for removing thrombogenic agents selected from the group consisting of prekallikrein activator (PKA) and Factor XIa; PKA and Factor XI; PKA Factor XIa, and Kallikrein; PKA, Factor XI and Kallikrein; and PKA, Factor XIa, Factor XI and Kallikrein from an immunoglobulin containing solution, the method comprising the steps of: contacting the solution with a support comprising immobilized negatively charged groups equilibrated at a pH in the range of higher than 3.8 to equal to or lower than 5.3 and with a support comprising immobilized positively charged groups equilibrated at a pH in the range of 7.0 to 8.2 to allow PKA binding to the positively charged groups and Factor XIa, Factor XI and/or Kallikrein binding to the negatively charged groups; and collecting unbound fractions comprising immunoglobulin.

2. The method according to claim 1 , wherein the negatively charged groups are equilibrated at a pH in the range of higher than 3.8 to equal to or lower than 5.0.

3. The method according to claim 1 , wherein the negatively charged groups are equilibrated at a pH in the range of equal to or higher than 4.0 to equal to or lower than 5.0.

4. The method according to claim 1 , wherein the negatively charged groups are equilibrated at a pH in the range of higher than 3.8 to equal to or lower than 4.7.

5. The method according to claim 1 , wherein the negatively charged groups are equilibrated at a pH of about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, or 4.7.

6. The method according to claim 1 , wherein the negatively charged groups are equilibrated at a pH in the range of higher than 3.8 to equal to or lower than 4.3.

7. The method according to claim 1 , wherein the negatively charged groups are equilibrated at a pH in the range of equal to or higher than 4.0 to equal to or lower than 4.3.

8. The method according to claim 1 , wherein the negatively charged groups are equilibrated at a pH in the range of equal to or higher than 4.1 to equal to or lower than 4.3.

9. The method according to claim 1 , wherein the support comprising immobilized negatively charged groups and/or the support comprising immobilized positively charged groups are in the form of a chromatographic material or a chromatographic membrane.

10. The method according to claim 1 , wherein the charged groups are immobilized to the support via a linker present between the support and the charged groups.

11. The method according to claim 10 , wherein the linker is selected from the group consisting of a protein, amino acid and peptide.

12. The method according to claim 1 , wherein the support comprising immobilized negatively charged groups and/or the support comprising immobilized positively charged group are chemically modified.

13. The method according to claim 1 , wherein the immobilized negatively charged groups are selected from the group consisting of derivatives of sulfonic and other sulfur containing acids, formic and other carboxylic acids, phosphoric and other phosphorous containing acids, nitrate and other nitrogen containing acids, and a combination thereof.

14. The method according to claim 13 , wherein the immobilized negatively charged groups are sulfur containing acids.

15. The method according to claim 14 , wherein the sulfur containing acids are sulfopropyl.

16. The method according to claim 13 , wherein the immobilized negatively charged groups are carboxylic acids.

17. The method according to claim 16 , wherein the carboxylic acids are carboxymethyl.

18. The method according to claim 1 , wherein the immobilized positively charged groups are selected from the group consisting of ammonium, alkyl ammonium, dialkylammonium, trialkyl ammonium, quaternary ammonium, alkyl groups, H+, Na+, K+, Ca2+, Mg2+, amino functional group, and a combination thereof.

19. The method according to claim 18 , wherein the immobilized positively charged groups are quaternary ammonium.

20. The method according to claim 19 , wherein the quaternary ammonium is Diethylaminoethyl (DEAE).

21. The method according to claim 1 , wherein contacting the solution with the support comprising the positively charged groups is carried out at a linear velocity in the range of 1 to 2 ml/min/cm2, and wherein the immunoglobulin containing solution has a temperature in the range of 2 to 22° C.

22. The method according to claim 1 , further comprising the steps of: contacting the solution, prior to contacting with the support comprising immobilized negatively charged groups, with a chromatographic material comprising three-dimensional cross-linked hydrophobic acrylic polymer.

Assignees

• Omrix Biopharmaceuticals Ltd

Inventors

• Mintz Roni
• Belyaev Oleg
• Nur Israel
• Bar Liliana
• Meidler Roberto

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07K16/065 Primary

  Purification, fragmentation · CPC title

• A61K39/39591

  Stabilisation, fragmentation · CPC title